A major Korean biopharmaceutical company co-developed a new cancer treatment product with a partner and wanted to gather unbiased opinions on the results of its early clinical development from leading key opinion leaders (KOLs) in the oncology field.

The client could not engage the desired population through its existing network within the short time frame due to bandwidth constraint and the concern that it might disclose highly confidential information.

After speaking with KOLs in the U.S. oncology field and learning about the quality of GLG’s network, the client approached GLG.

Within a few days, GLG screened more than 400 U.S. oncologists and delivered a solid candidate list. From that list, the client selected optimal Network Members and GLG arranged screening calls to evaluate them.

The client had heightened concerns about the sharing of highly confidential information. As such, GLG worked closely with the client and a selected number of Network Members to address those concerns and reached a workable solution. GLG, as the facilitator of the entire consultation process, also shared the survey questionnaire to help the client gain expert opinion on the new product.

The client confirmed engagement with three of the listed, leading oncologists who then provided in-depth written reports outlining their thoughts on the clinical development and technical feasibility of the product. They also shared their advice on the direction of the development going forward.